Article

Holbrook, L., Keeton, S., Sasikumar, P., Nock, S., Gelzinis, J., Brunt, E., Ryan, S., Pantos, M. M., Verbetsky, C. A., Gibbins, J. M. ORCID: https://orcid.org/0000-0002-0372-5352 and Kennedy, D. R. (2020) Zafirlukast is a broad-spectrum thiol isomerase inhibitor that inhibits thrombosis without altering bleeding times. British Journal of Pharmacology. ISSN 1476-5381 (In Press)

Nicolson, P. L., Nock, S. H., Hinds, J., Garcia-Quintanilla, L., Smith, C. W., Campos, J., Brill, A., Pike, J. A., Khan, A. O., Poulter, N. S., Kavanagh, D. M., Watson, S., Watson, C. N., Clifford, H., Huissoon, A. P., Pollitt, A. Y., Eble, J. A., Pratt, G., Watson, S. P. and Hughes, C. E. (2020) Low dose Btk inhibitors selectively block platelet activation by CLEC-2. Haematologica, 105 (1). ISSN 1592-8721 doi: https://doi.org/10.3324/haematol.2019.218545

Nicolson, P. L. R., Hughes, C. E., Watson, S., Nock, S. H., Hardy, A. T., Watson, C. N., Montague, S. J., Malcor, J.-D., Thomas, M. R., Pollitt, A. Y., Tomlinson, M. G., Pratt, G. and Watson, S. P. (2018) Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation to GPVI. Haematologica, 103 (12). pp. 2097-2108. ISSN 1592-8721 doi: https://doi.org/10.3324/haematol.2018.193391

Bye, A. P., Unsworth, A. J., Desborough, M. J., Hildyard, C. A. T., Appleby, N., Bruce, D., Kriek, N., Nock, S. H., Sage, T., Hughes, C. E. and Gibbins, J. M. (2017) Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. Blood Advances, 1 (26). pp. 2610-2623. ISSN 2473-9529 doi: https://doi.org/10.1182/bloodadvances.2017011999